hip hip horay !, page-5

I held Cellestis from shortly after IPO to just before Christmas 2010. So it definitely made money - but I still wish I had sold at $4 (hindsight is a wonderful thing).

There's a competing product (one I shall not name here!) with a similar (price, performance) product but with the 'celebrity factor' in Bill Gates and WHO and whoever is Hollywood-world-health-ambassador-starlet-of-the-day.

At some point a R&D boffin with CST may pull something really special out of the bag. But for now I reckon sp is driven by dividend, and that means sales.

QFT sales will need to expand amazingly to get beyond $3.

Finally... *IF* the recall report above is correct, it's probably only going to be a manufacturing fault with a batch or three. That won't kill the company or affect industry purchasing.